Helgstrand, J. T. et al. Tendencies in incidence and 5-year mortality in males with newly recognized, metastatic prostate cancer-A population-based evaluation of two nationwide cohorts. Most cancers 124, 2931–2938 (2018).
Hamid, A. A. et al. Metastatic hormone-sensitive prostate most cancers: towards an period of adaptive and customized remedy. Am. Soc. Clin. Oncol. Educ. E-book 43, e390166 (2023).
Kyriakopoulos, C. E. et al. Chemohormonal remedy in metastatic hormone-sensitive prostate most cancers: long-term survival evaluation of the randomized section III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080–1087 (2018).
Gravis, G. et al. Burden of metastatic castrate naive prostate most cancers sufferers, to determine males extra more likely to profit from early docetaxel: additional analyses of CHAARTED and GETUG-AFU15 research. Eur. Urol. 73, 847–855 (2018).
Vapiwala, N., Hofman, M. S., Murphy, D. G., Williams, S. & Sweeney, C. Methods for analysis of novel imaging in prostate most cancers: placing the horse again earlier than the cart. J. Clin. Oncol. 37, 765–769 (2019).
Nyquist, M. D. et al. Mixed TP53 and RB1 loss promotes prostate most cancers resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 31, 107669 (2020).
Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate most cancers lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78–83 (2017).
Annala, M. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate most cancers. Most cancers Discov. 8, 444–457 (2018).
de Bono, J. et al. Olaparib for metastatic castration-resistant prostate most cancers. N. Engl. J. Med. 382, 2091–2102 (2020).
Abida, W. et al. Rucaparib in males with metastatic castration-resistant prostate most cancers harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 38, 3763–3772 (2020).
Abida, W. et al. Evaluation of the prevalence of microsatellite instability in prostate most cancers and response to immune checkpoint blockade. JAMA Oncol. 5, 471–478 (2019).
Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate most cancers (IPATential150): a multicentre, randomised, double-blind, section 3 trial. Lancet 398, 131–142 (2021).
Cooper, C. S. et al. Evaluation of the genetic phylogeny of multifocal prostate most cancers identifies a number of impartial clonal expansions in neoplastic and morphologically regular prostate tissue. Nat. Genet. 47, 367–372 (2015).
Espiritu, S. M. G. et al. The evolutionary panorama of localized prostate cancers drives medical aggression. Cell 173, 1003–1013 (2018).
Most cancers Genome Atlas Analysis Community. The molecular taxonomy of major prostate most cancers. Cell 163, 1011–1025 (2015).
Schaeffer, E. M. et al. NCCN tips insights: prostate most cancers, model 1.2023. J. Natl. Compr. Canc. Netw. 20, 1288–1298 (2022).
Mateo, J. et al. Genomics of deadly prostate most cancers at analysis and castration resistance. J. Clin. Make investments. 130, 1743–1751 (2020).
Stopsack, Okay. H. et al. Oncogenic genomic alterations, medical phenotypes, and outcomes in metastatic castration-sensitive prostate most cancers. Clin. Most cancers Res. 26, 3230–3238 (2020).
Wyatt, A. W. et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate most cancers. J. Natl. Most cancers Inst. 109, djx118 (2017).
Herberts, C. et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate most cancers. Nature 608, 199–208 (2022).
Vandekerkhove, G. et al. Circulating tumor DNA abundance and potential utility in de novo metastatic prostate most cancers. Eur. Urol. 75, 667–675 (2019).
Kohli, M. et al. Scientific and genomic insights into circulating tumor DNA-based alterations throughout the spectrum of metastatic hormone-sensitive and castrate-resistant prostate most cancers. eBioMedicine 54, 102728 (2020).
Van der Eecken, Okay. et al. Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate most cancers: a scientific evaluation. Eur. Urol. Oncol. 4, 914–923 (2021).
Sweeney, C. J. et al. Chemohormonal remedy in metastatic hormone-sensitive prostate most cancers. N. Engl. J. Med. 373, 737–746 (2015).
Fizazi, Okay. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate most cancers. N. Engl. J. Med. 377, 352–360 (2017).
Fizazi, Okay. et al. Abiraterone plus prednisone added to androgen deprivation remedy and docetaxel in de novo metastatic castration-sensitive prostate most cancers (PEACE-1): a multicentre, open-label, randomised, section 3 examine with a 2 × 2 factorial design. Lancet 399, 1695–1707 (2022).
Hussain, M. et al. Darolutamide plus androgen-deprivation remedy and docetaxel in metastatic hormone-sensitive prostate most cancers by illness quantity and danger subgroups within the section III ARASENS trial. J. Clin. Oncol. 41, 3595–3607 (2023).
Gilson, C. et al. Genomic profiles of de novo high- and low-volume metastatic prostate most cancers: outcomes from a 2-stage feasibility and prevalence examine within the STAMPEDE trial. JCO Summary. Oncol. 4, 882–897 (2020).
Hussain, M. et al. Tumor genomic testing for >4,000 males with metastatic castration-resistant prostate most cancers within the section III trial PROfound (Olaparib). Clin. Most cancers Res. 28, 1518–1530 (2022).
Annala, M. et al. Evolution of castration-resistant prostate most cancers in ctDNA throughout sequential androgen receptor pathway inhibition. Clin. Most cancers Res. 27, 4610–4623 (2021).
Jayaram, A. et al. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate most cancers: a biomarker evaluation of a multicenter worldwide trial. Ann. Oncol. 32, 726–735 (2021).
Annala, M. et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate most cancers: a multicentre, randomised, open-label, section 2 trial. Ann. Oncol. 32, 896–905 (2021).
Mayrhofer, M. et al. Cell-free DNA profiling of metastatic prostate most cancers reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Med. 10, 85 (2018).
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of superior cancers. Nat. Genet. 50, 1189–1195 (2018).
Robinson, D. et al. Integrative medical genomics of superior prostate most cancers. Cell 162, 454 (2015).
Black, J. R. M. & McGranahan, N. Genetic and non-genetic clonal range in most cancers evolution. Nat. Rev. Most cancers 21, 379–392 (2021).
Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity throughout 2,658 human most cancers genomes. Cell 184, 2239–2254 (2021).
Løvf, M., Zhao, S., Axcrona, U. & Johannessen, B. Multifocal major prostate most cancers reveals excessive diploma of genomic heterogeneity. Eur. Urol. 75, 498–505 (2019).
Boysen, G. et al. SPOP-mutated/CHD1-deleted deadly prostate most cancers and abiraterone sensitivity. Clin. Most cancers Res. 24, 5585–5593 (2018).
Swami, U. et al. Affiliation of SPOP mutations with outcomes in males with de novo metastatic castration-sensitive prostate most cancers. Eur. Urol. 78, 652–656 (2020).
Litchfield, Okay. et al. Consultant sequencing: unbiased sampling of stable tumor tissue. Cell Rep. 31, 107550 (2020).
Emmett, L. et al. The additive diagnostic worth of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage within the analysis of prostate most cancers (PRIMARY): a potential multicentre examine. Eur. Urol. 80, 682–689 (2021).
Tomlins, S. A. et al. Actual-world efficiency of a complete genomic profiling check optimized for small tumor samples. JCO Summary. Oncol. 5, PO.20.00472 (2021).
Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals excessive concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).
Hamid, A. A. et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate most cancers. Eur. Urol. 76, 89–97 (2019).
Nava Rodrigues, D. et al. RB1 heterogeneity in superior metastatic castration-resistant prostate most cancers. Clin. Most cancers Res. 25, 687–697 (2019).
van de Haar, J. et al. Restricted evolution of the actionable metastatic most cancers genome underneath therapeutic stress. Nat. Med. 27, 1553–1563 (2021).
Clarke, N. W. et al. Abiraterone and olaparib for metastatic castration-resistant prostate most cancers. NEJM Evid. 1, EVIDoa2200043 (2022).
Agarwal, N. et al. TALAPRO-2: section 3 examine of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) remedy in sufferers (pts) with metastatic castration-resistant prostate most cancers (mCRPC). J. Clin. Oncol. 41, LBA17 (2023).
Herberts, C. & Wyatt, A. W. Technical and organic constraints on ctDNA-based genotyping. Tendencies Most cancers. 7, 995–1009 (2021).
Deek, M. P. et al. The mutational panorama of metastatic castration-sensitive prostate most cancers: the spectrum principle revisited. Eur. Urol. 80, 632–640 (2021).
Kumar, A. et al. Substantial interindividual and restricted intraindividual genomic range amongst tumors from males with metastatic prostate most cancers. Nat. Med. 22, 369–378 (2016).
Gundem, G. et al. The evolutionary historical past of deadly metastatic prostate most cancers. Nature 520, 353–357 (2015).
Parker, C. C. et al. Radiotherapy to the first tumour for newly recognized, metastatic prostate most cancers (STAMPEDE): a randomised managed section 3 trial. Lancet 392, 2353–2366 (2018).
Lumen, N. et al. The position of cytoreductive radical prostatectomy within the remedy of newly recognized low-volume metastatic prostate most cancers. outcomes from the native remedy of metastatic prostate most cancers (LoMP) registry. Eur. Urol Open Sci. 29, 68–76 (2021).
Phillips, R. et al. Outcomes of commentary vs stereotactic ablative radiation for oligometastatic prostate most cancers: the ORIOLE section 2 randomized medical trial. JAMA Oncol 6, 650–659 (2020).
Reiter, J. G. et al. Lymph node metastases develop by means of a wider evolutionary bottleneck than distant metastases. Nat. Genet. 52, 692–700 (2020).
Nguyen, B. et al. Genomic characterization of metastatic patterns from potential medical sequencing of 25,000 sufferers. Cell 185, 563–575 (2022).
Berglund, E. et al. Spatial maps of prostate most cancers transcriptomes reveal an unexplored panorama of heterogeneity. Nat. Commun. 9, 2419 (2018).
Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG tips on prostate cancer-2020 replace. half 1: screening, analysis, and native remedy with healing intent. Eur. Urol. 79, 243–262 (2020).
Buelens, S. et al. Multicentre, potential examine on native remedy of metastatic prostate most cancers (LoMP examine). BJU Int. 129, 699–707 (2022).
van Leenders, G. J. L. H. et al. The 2019 Worldwide Society of Urological Pathology (ISUP) consensus convention on grading of prostatic carcinoma. Am. J. Surg. Pathol. 44, e87–e99 (2020).
Turkbey, B. et al. Prostate imaging reporting and information system model 2.1: 2019 replace of prostate imaging reporting and information system model 2. Eur. Urol. 76, 340–351 (2019).
Verbeke, S. L. J. et al. A reappraisal of hemangiopericytoma of bone; evaluation of circumstances reclassified as synovial sarcoma and solitary fibrous tumor of bone. Am. J. Surg. Pathol. 34, 777–783 (2010).
Roth, A. et al. PyClone: statistical inference of clonal inhabitants construction in most cancers. Nat. Strategies 11, 396–398 (2014).
Satas, G., Zaccaria, S., El-Kebir, M. & Raphael, B. J. DeCiFering the elusive most cancers cell fraction in tumor heterogeneity and evolution. Cell Methods 12, 1004–1018 (2021).
Niknafs, N., Beleva-Guthrie, V., Naiman, D. Q. & Karchin, R. Subclonal hierarchy inference from somatic mutations: automated reconstruction of most cancers evolutionary timber from multi-region subsequent technology sequencing. PLoS Comput. Biol. 11, e1004416 (2015).
Tarabichi, M. et al. A sensible information to most cancers subclonal reconstruction from DNA sequencing. Nat. Strategies 18, 144–155 (2021).
